PA
IMNM icon

Parallel Advisors’s Immunome IMNM Stock Holding History

Parallel Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-93
Closed -$988 – 3589
2024
Q4 		$988 Buy
93
+65
+232% +$785 ﹤0.01% 3113
2024
Q3 		$409 Hold
28
– – ﹤0.01% 3211
2024
Q2 		$339 Buy
+28
New +$438 ﹤0.01% 3144

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Parallel Advisors's IMNM Position: Q1 2025 in Review

Parallel Advisors sold out of Immunome (IMNM) in Q1 2025, closing a stake of 93 shares — an estimated $988 sold.

Parallel Advisors first reported a position in IMNM in Q2 2024 and held it in 3 quarters. The position peaked at $988 in Q4 2024. 142 funds tracked by Wall St. Rank hold IMNM as of Q1 2025.

  • Parallel Advisors reported no remaining Immunome position as of Q1 2025 after selling out during the quarter.
  • Parallel Advisors sold 93 Immunome shares in Q1 2025, an estimated $988.
  • Parallel Advisors first reported a position in Immunome in Q2 2024 and held it in 3 quarters.
  • Parallel Advisors's Immunome position peaked at $988 in Q4 2024.
  • 142 funds tracked by Wall St. Rank held Immunome as of Q1 2025.

Based on Parallel Advisors's 13F filing for Q1 2025, filed 8 Apr 2025.